In a landmark announcement, a new and highly effective HIV prevention drug, Lenacapavir, is set to be made available at a drastically reduced cost in over 100 low- and middle-income countries within the next two years.
This breakthrough development offers a new beacon of hope in the global fight against HIV/AIDS, particularly for Africa, the continent most affected by the epidemic.
We have since established that the government of the United States, in collaboration with the Ugandan Ministry of Health, will introduce lenacapavir in 2026.
Lenacapavir offers a highly effective and convenient HIV prevention option for individuals at high risk of HIV acquisition. Clinical trials show more than 99% of people on lenacapavir remained HIV negative.
The move is expected to give millions access to a life-changing treatment and could be a pivotal step toward ending the epidemic for good.
Affordable Access and Lasting Protection
Lenacapavir, a long-acting injectable, is administered just twice a year, providing six months of continuous protection against HIV infection with each dose.
This offers a significant advantage over the current standard, PrEP, which requires a daily pill. The daily regimen of PrEP can be difficult for patients to maintain and often carries a social stigma, which has limited its reach.
According to the Gates Foundation, only 18% of those who could benefit from PrEP currently have access.
Reduced Price Offers New Hope
The most impactful part of the announcement is the price reduction. While the initial annual cost of Lenacapavir is US$28,000 (about Shs97,884,080), a new agreement forged by the Clinton Health Access Initiative and the Gates Foundation will slash the price to just US$40 (about Shs140,131) per person annually.
This represents a reduction of over 99%, making the treatment an affordable necessity rather than a luxury for low-income countries.
Targeting Vulnerable Communities and Championing Accessibility
Experts believe that long-acting injectables like Lenacapavir could be a game-changer for the most vulnerable populations, including adolescent girls and young women, and other at-risk groups. Professor Saiqa Mullick of the South African research institute Wits RHI emphasised that the drug has the “potential to transform prevention” for communities that struggle with frequent clinic visits.
Lenacapavir has already received official backing from the World Health Organisation and has been approved by major regulatory bodies like the U.S. Food and Drug Administration. While the generic version is still pending regulatory approval, the goal is to have it available by 2027. One study suggests that increasing access to this new injection to just 4% of the population could prevent up to 20% of new HIV infections.
This breakthrough comes at a crucial time, as global health efforts face funding cuts. With over 40 million people currently living with HIV worldwide, and South Africa alone having almost eight million cases, this new affordable drug is a monumental step toward ensuring a healthier, more secure future for millions across the continent.